Ítem
Solo Metadatos

Fabry disease in Latin America: Data from the fabry registry

Mostrar el registro sencillo de la publicación
dc.creatorVillalobos, J.spa
dc.creatorPolitei, J. M.spa
dc.creatorMartins, A. M.spa
dc.creatorCabrera, G.spa
dc.creatorAmartino, H.spa
dc.creatorLemay, R.spa
dc.creatorOspina, S.spa
dc.creatorOrdoñez, S. Suarezspa
dc.creatorVaras, C.spa
dc.date.accessioned2020-05-25T23:55:46Z
dc.date.available2020-05-25T23:55:46Z
dc.date.created2013spa
dc.description.abstractThe purpose of these analyses was to characterize demographic and baseline clinical characteristics of Latin American patients with Fabry disease compared to that of patients in the rest of the world. Observational data reported to the Fabry Registry were obtained from untreated patients or prior to treatment with enzyme replacement therapy. As of October 1, 2010, 3,752 patients were enrolled in the Fabry Registry worldwide, including 333 patients within Latin America. Latin American patients tended to be younger than Fabry Registry patients enrolled in the rest of the world: Mean current age 35.5 years versus 39.2 years for men (p less than 0.05 by t-test), mean age 37.8 years versus 43.6 years for women (p less than 0.05 by t-test). A smaller percentage of Latin American patients have received enzyme replacement therapy, compared to patients in the rest of the world: 67% versus 80% for men, and 19% versus 39% of women, respectively. Thirty-one percent of men and 22% of women in Latin America reported experiencing a significant cardiovascular, renal, or cerebrovascular event, at a mean age of 35 ± 12.6 years in men and 44 ± 12.3 years in women. Cardiovascular events were the most common type of initial clinical event among men and women in Latin America. The medical community in Latin America should be aware of Fabry disease as a possible cause of renal or cardiac dysfunction. Increased awareness will facilitate prompt diagnosis and initiation of treatment. © SSIEM and Springer-Verlag Berlin Heidelberg 2012.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/8904_2012_165
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22209
dc.language.isoengspa
dc.publisherSpringerspa
dc.relation.citationEndPage99
dc.relation.citationStartPage91
dc.relation.citationTitleJIMD Reports
dc.relation.citationVolumeVol. 8
dc.relation.ispartofJIMD Reports, Vol.8,(2013); pp. 91-99spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85032357165&doi=10.1007%2f8904_2012_165&partnerID=40&md5=8525152ec5fd23bdeb77f727ac31a610spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordChronic kidney diseasespa
dc.subject.keywordChronic kidney disease stagespa
dc.subject.keywordEnzyme replacement therapyspa
dc.subject.keywordFabry diseasespa
dc.subject.keywordLeft ventricular hypertrophyspa
dc.titleFabry disease in Latin America: Data from the fabry registryspa
dc.typebookParteng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaParte de librospa
Archivos
Colecciones
Artículos